Kantipur Pharmaceuticals Lab has decided to issue ordinary shares (IPO)
to the public. To proceed with the share issuance process, the company has
appointed Muktinath Capital as the Issue Manager.
In a program held at the company’s corporate office in Bal Kumari,
Lalitpur, Nawraj Paudyal, MD of Kantipur Pharmaceuticals Lab, and Kabindra
Dhwaj Joshi, CEO of Muktinath Capital, signed the agreement. The company is
planning to sell 14.86% of its issued capital, equivalent to 1.1 million
ordinary shares, to the public.
Established in 2018, this company has obtained a production and
marketing registration certificate from the Department of Drug Administration
and has been engaged in the research, production, and distribution of
veterinary medicines and nutritional supplements. The company is in the process
of being certified with GMP, FAMIQS, and other similar certifications. Currently,
the company has received approval to produce 61 different types of medicines
from the Department of Drug Administration, out of which 13 are already being
sold and distributed in the Nepali market with necessary sales and distribution
certificates. The company is in the process of
obtaining distribution certificates for the remaining medicines.
In addition, the company is producing and distributing 21 other
nutritional supplements. With the primary objective of contributing to animal
health in Nepal and international markets, this company is the first in the
veterinary pharmaceutical industry to issue shares to the general public.
